What Kester Capital does

Kester Capital is a London-based private equity firm operating as Kester Capital LLP, founded in 2013 and headquartered at 14-16 Bruton Place in Mayfair. The firm invests exclusively in two sectors — Technology and Life Sciences — targeting equity investments of up to £75 million in mid-market primary buyouts alongside ambitious management teams. Its investment focus spans B2B software (e.g., Optibrium's AI-enabled drug discovery platform, Re-flow field service management software, Addresscloud geospatial risk analytics), data and information services (Vixio regulatory intelligence, DC Byte data centre market intelligence, Nutritics food data), and Life Sciences services (Evestia Clinical CRO, GXP Engaged GxP auditing, Kintiga market access consulting, Rephine GMP/GCP auditing). The firm manages four funds; Fund IV closed at a £425m hard cap in November 2025, more than double Fund III's £200m close in March 2024, with both materially oversubscribed.

Kester generates revenue through two streams typical of private equity fund managers: (1) recurring management fees on committed capital across its fund series, and (2) carried interest on investment returns above preferred return thresholds. The firm has demonstrated an exceptional and consistent exit record — four consecutive exits above 4x (including Avania at 8.4x, Vixio at 4.8x, Atec at 4x and Jollyes at 4.3x) and eight consecutive exits above 3x — alongside portfolio-level revenue scaling such as Avania's >5x revenue growth, Atec's 3x revenue / 4x profit, and Vixio's >60% IRR with NRR>100%. Operating geographies for portfolio companies span the UK, continental Europe, the US, Asia Pacific (NZ, India), and Turkey.

The firm's distribution model is direct and relationship-driven: investment opportunities are originated by Kester's own sector-specialist professionals, and fund capital is sourced directly from blue-chip institutional LPs (pension funds, endowments, foundations, family offices) across the US, Europe and Asia without intermediaries. Portfolio-level technology stack is heterogenous across holdings, ranging from AI-powered drug discovery platforms and geospatial risk models to subscription regulatory information services and GxP audit management tools. The Kester Foundation, established in 2022, receives 10% of carry from Fund III onwards and supports charitable causes including the Francis Crick Institute, the Sutton Trust and The Fore.

Name

Kester Capital

Legal name

Kester Capital LLP

Website

http://www.kestercapital.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Kester Capital is a London-based private equity firm focused exclusively on Technology and Life Sciences. It deploys equity investments of up to £75 million in mid-market primary buyouts, currently investing from its £425 million Fund IV across B2B software, data services, and life sciences businesses.

Ownership category

akta.pro rank

Product category

Private Equity Investing

NAICS

Other Investment Pools and Funds (5259)

SIC

Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Large-Cap / Mega-Fund Buyout (FSANABAA)

akta.pro secondary industry

Corporate Finance & Capital Advisory (BPAHADAB)

Keywords

• Private equity investing
• Mid-market buyouts
• Technology sector investments
• Life sciences investments
• Growth capital

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Management Fees: Kester Capital generates management fees on its committed capital under management across its funds (Fund I through Fund IV). Fees are charged on committed capital throughout the investment period.
2. Carried Interest (Performance Fees): Kester Capital earns carried interest on investment returns above preferred return thresholds. The firm has delivered exceptional returns including four consecutive exits over 4x and eight consecutive exits over 3x. The Kester Foundation receives 10% of carry generated by Fund III and future funds.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Kester Capital is a UK mid-market private equity firm that invests equity of up to £75 million in primary buyouts of ambitious Technology and Life Sciences businesses. The firm operates sector-focused funds (currently Fund III and Fund IV) that partner with management teams and founders to scale high-growth businesses into market leaders, generating returns through management fees on committed capital and carried interest on successful exits.

Product overview

Kester Capital is a UK-based private equity firm offering equity investments of up to £75 million to ambitious Technology and Life Sciences businesses. The firm operates a platform investment approach across two sectors: Technology (including Software, Data & Information Services, and Tech-enabled Services) and Life Sciences (including CRO services, GxP auditing, and market access consulting). The portfolio includes B2B SaaS platforms (Nutritics, Addresscloud, Re-flow), data and information services (DC Byte, VIXIO, Optibrium), and specialised healthcare services (Evestia Clinical, GXP Engaged, Kintiga, Rephine), with former investments including Avania (medtech CRO) and The Boundary (architectural visualisation software).

Differentiator

Problem solved

Functional benefit

Brands

• Kester Foundation: A registered charitable foundation established in 2022 that uses its share of carried interest to support third party charities and not-for-profit entities including The Francis Crick Institute, The Sutton Trust, and The Fore.

Products and services

• Kester Capital Fund IV Kester Capital's fourth flagship private equity fund, focused on Technology and Life Sciences, targeting equity investments of up to £75 million per transaction. Investors (LPs) commit capital to the closed-end fund and receive carried interest-style returns on successful exits.
• Kester Capital Fund III Kester Capital's third flagship private equity fund, deployed into Technology and Life Sciences primary buyouts, with 10% of carried interest committed to the Kester Foundation.
• Technology Sector Investment Services Equity investments of up to £75 million in Technology businesses across three sub-verticals: B2B Software (horizontal or vertical applications solving complex problems), Data & Information Services (subscription-based data and insight providers with clear IP), and Tech-enabled Services (technology-enabled B2B services in high-growth markets with scalable models).
• Life Sciences Sector Investment Services Equity investments in providers of outsourced services, products and technology to pharma, biotech and medtech customers with strong scientific, regulatory and technical expertise, supporting them through global scaling, C-suite capability building, operational professionalisation, and strategic acquisitions.

Quantifiable outcome

• Kester has delivered four consecutive exits over 4x and eight consecutive exits over 3x across its fund history.
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Three partnerships are on record, tiered minor.

• The Francis Crick InstituteminorOthersThe Kester Foundation (established 2022) supports The Francis Crick Institute, a biomedical research facility focused on understanding how living things work and driving benefits for human health.
• The Sutton TrustminorOthersThe Kester Foundation supports The Sutton Trust, the UK's leading social mobility charity, which empowers young people to access life-changing opportunities through programmes and research.
• The ForeminorOthersThe Kester Foundation supports The Fore, the only venture philanthropy fund in the UK dedicated to small charities, focused on helping the best solutions scale from grassroots to nationwide impact.

Scale indicators16 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• ECI Partners: UK mid-market private equity firm with a long-standing focus on software, tech-enabled services, and specialist B2B businesses — closely matching Kester's Tech vertical and mid-market equity cheque size.
• LDC (Lloyds Development Capital): One of the most active UK mid-market private equity investors with broad sector exposure including technology and healthcare services, operating with a comparable mid-market equity ticket to Kester Capital.
• Mobeus Equity Partners: UK smaller-mid-market private equity firm investing in tech-enabled, B2B services, and specialist software businesses — comparable to Kester in deal approach, though typically at the smaller end of the equity-cheque range.
• Lyceum Capital: UK mid-market private equity firm focused on software, technology-enabled services, and data businesses — a close peer to Kester on the Technology side of its investment strategy.
• Livingbridge: UK mid-market growth and private equity firm investing in software, tech-enabled services, and consumer, with a focus and engagement model very similar to Kester's sector-specialist approach.
• Inflexion: UK mid-market private equity firm focused on software, services, and life sciences, with a similar sweet-spot equity cheque size and a comparable sector-specialist investment thesis to Kester Capital.
• Phoenix Equity Partners: UK mid-market private equity firm investing in growth-oriented, tech-enabled, and consumer-facing businesses, with comparable equity cheque sizes and sector breadth to Kester Capital.

Regional players

• Stirling Square Capital Partners: European mid-market private equity firm focused on business services, technology, and specialist industrials — a regional European competitor with overlapping interest in Kester's Tech-enabled Services and data subsectors.

Broad incumbents

• Bridgepoint: Large European mid-market private equity investor with a diversified sector mandate including technology, healthcare, and business services — a broader incumbent that competes with Kester for select assets, especially in Life Sciences services.
• Hg (Hg Capital): A larger UK-headquartered technology and software-focused private equity firm; a broader incumbent that operates in the same B2B software and tech-enabled services space as Kester but at materially greater scale and AUM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kester-capital
• Xx.com/kestercapital

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kester Capital